Formycon AG I (FYB.DE)
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland.
18.90-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-28.5%
The outlook
Formycon AG I currently reads as neutral based on strong buy — 1.4 avg of 6 analysts, below its 50- & 200-day averages, 22% of the way from its 52-week low to high, avg target +110% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 6 analysts
Price trendBelow its 50- & 200-day averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +110% vs current price
Analyst price target
~12-month · 6 analysts39.67average target+109.9% vs now
Now 18.90
Low 30.00High 51.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
—
52-wk high
29.65
52-wk low
15.80
50-day avg
19.57
200-day avg
21.11
Trailing P/E
—